CD274 and non-small cell lung carcinoma: There is a multitude of new NSCLC drug targets, e.g., NTRK1-3 and RET gene fusions, MET exon 14 skipping mutations, KRAS G12C substitutions, etc. In addition, administration of several inhibitors of immune checkpoints involves testing for PD-L1 expression (1–3).